AsianScientist (May 20, 2013) – RuiYi Inc. has entered into an exclusive license and collaborative development agreement with Genor Biopharma for the development of RYI-008, a novel anti-IL-6 monoclonal antibody that targets inflammation and cancer, in China.
RYI-008, also known as ARGX-109, is, according to RuYi Inc., a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer.
The antibody was discovered by arGEN-X, Ghent Belgium, utilizing the arGEN-X SIMPLE Antibody™ technology, and exclusively licensed to RuiYi to develop and commercialize globally.
“RYI-008, with its unprecedented femtomolar potency and amazing long half-life has a therapeutic profile of once monthly, low milligram, subcutaneous dosing,” said Paul Grayson, president and CEO of RuiYi. “RYI-008 is a tremendous candidate for this novel development strategy, with approximately 4.1 million biologic treatment naïve rheumatoid arthritis patients in China in need of a cost effective therapeutic option. The team at Genor has deep global development experience and strong commercial, regulatory, and government relationships in China, making them the ideal development partner. We look forward to working with them to deliver novel, breakthrough therapeutics for the Chinese healthcare system.”
——
Source: RuYi Inc.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
